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Abstract
Cystic fibrosis (CF) is an autosomal recessive genetic disorder resulting from genetic defects 
in the gene coding for the cystic fibrosis transmembrane conductance  regulator (CFTR) 
protein. CFTR dysfunction in patients with CF leads to a number of  pleiotropic manifes-
tations with the prime pathology being mucus plugging in the airways and  paranasal 
sinuses. Patients with CF are prone to polymicrobial infections and the  airway micro-
biome in such patients changes continuously and evolves over time. The  composition 
of the airway microbiome in CF patients is dependent on a number of  factors includ-
ing geographic variation, type of genetic mutation (e.g., ΔF508),  antibiotic exposures, 
and chronic infection with certain pathogenic bacteria (e.g., Pseudomonas  aeruginosa). 
Proteomic and genomic approaches to understanding the microbiome of patients with 
CF have provided new insights into the pathogenesis of this disease.  High‐throughput 
pyrosequencing, Sanger sequencing, and phylogenetic microarray analysis have enabled 
the recognition of multiple lineages and clonal populations of a single bacterial species 
within the same patient. This provides a unique opportunity to explore novel therapeutic 
approaches to this disease (for instance, use of probiotics and environmental manipula-
tion) and potentially translate them into bedside clinical interventions.
Keywords: cystic fibrosis, microbiome, dysbiosis, Pseudomonas aeruginosa, burkholderia 
cenocepacia
1. Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the CFTR 
(cystic fibrosis transmembrane conductance regulator) gene [1]. CF is most prevalent in the 
Caucasian population and is a common life‐limiting disease [2]. CFTR is expressed on the  apical 
surface of epithelial cells of the respiratory, gastrointestinal, pancreatic and  reproductive tracts, 
and sweat glands [3]. The prime function of CFTR ion channel is to transport chloride ions 
across epithelial surfaces in order to maintain the osmotic gradient. Chloride ions are actively 
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pumped out into the luminal side of the gastrointestinal and  respiratory tracts, which decrease 
water potential on the luminal side. Subsequently, water molecules move from a higher 
osmotic potential to a lower osmotic potential (down the osmotic gradient) and  combine with 
mucin glycoproteins to keep them adequately hydrated. This in turn helps to maintain the thin 
consistency of the mucus layer, which is essential for optimal  mucociliary function [4]. Thick 
and viscid mucus caused by a defect in  chloride‐conducting transmembrane channel results 
in stagnation of mucus. Moreover, CFTR  channel also plays an important role in regulating 
the transepithelial transport of sodium and  bicarbonate ions [5]. Defective CFTR functioning 
leads to an increase in pH of the mucus layer, which compromises the innate immune system 
and promotes inflammation. Defects in innate immunity and chronic inflammation predis-
pose patients to recurrent pulmonary infections, which result in permanent lung damage—the 
prime cause of morbidity and mortality [6]. Pulmonary system is not the only organ‐system 
affected in CF; endocrine, gastrointestinal, and reproductive systems are also involved in this 
multisystem disorder [3].
The human microbiome project aims to identify and characterize microbial flora of healthy and 
diseased individuals [7]. Understanding the role of infectious pathogens in the  pathogenesis 
of CF in general and pulmonary exacerbations and lung damage in particular has enabled the 
scientific community to devise new treatment modalities for CF patients, which can poten-
tially improve outcomes and survival in such patients. In patients with CF,  different bacteria 
inhabit different parts of the lung at various stages of the disease and persistent inflamma-
tion in the lungs can change and modify the composition of the microbiome [8]. For instance, 
methicillin‐sensitive Staphylococcus aureus (MSSA) and Hemophilus influenzae are common 
pathogens early in life of such patients [9]. As the disease progresses, more  virulent patho-
gens—such as Pseudomonas aeruginosa and methicillin‐resistant S. aureus (MRSA)—invade 
the lung and cause pulmonary damage [10]. By understanding the evolution of the CF 
microbiome, we can gain further insights into the natural course of CF. This in turn can have 
important implications for developing interventions that can halt or reverse the course of 
progressive pulmonary damage and prolong survival and quality of life in CF patients [11]. 
In the following pages, we discuss the CF microbiome, its evolution and heterogeneity in CF 
patients, interaction between different bacteria within the CF lung and the factors that poten-
tially affect the CF microbiome.
2. The microbiome
As mentioned previously, the human microbiome project aims to identify and  characterize 
microbial flora of healthy and diseased individuals [7]. There is a diversity of microbes in 
every single human being i.e., diversity being defined as the number and distribution of 
a  particular type of organism in a body habitat. Every human has particular and distinct 
microbes;  dysbiosis (alteration in composition and balance) of these microbes is now thought 
to  underlie the pathogenesis of many diseases, such as inflammatory bowel disease, Clostridium 
difficile (CD) colitis, bacterial vaginosis, obesity, and CF [12]. The human  microbiome plays a 
very important role in human biology, defense mechanisms, metabolic processes (such as 
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 digestion, absorption, and assimilation) and even pathogenesis of acute and chronic dis-
eases [13]. For instance, CD colitis is a disease that arises as a consequence of interaction 
of  bacterial virulence factors, host immune mechanism and the intestinal  microbiome [14]. 
Research  studies have shown that variability in the innate host response may also impact 
upon the severity of CD colitis, and this variation may be accounted for by alterations in 
the gut  microbiota [15]. Based on improved understanding of the pathogenesis of CD colitis, 
fecal microbiota transplantation (FMT) and other novel types of bacteriotherapy have become 
potentially effective treatment options for this deadly disease [16].
Another example of a disease where microbiota plays a major role in pathogenesis is Crohn's 
disease. The exact cause of Crohn's disease is unknown; however, evidence suggests that 
microbiota contribute to the underlying pathology and disease development [17]. No  single 
bacterium has been convincingly shown to contribute to the overall pathogenesis of Crohn's 
disease. Instead, dysbiosis (bacterial imbalance) is more widely accepted as a  leading 
 factor in the disrupted host immune system cross‐talk that results in subsequent  intestinal 
inflammation [18]. Depletion of symbiont (beneficial) microbes (including Firmicutes, 
Bifidobacteriaceae, and Clostridia) in conjunction with an increase in pathobiont ( harmful) 
microbes (such as Bacteroidetes and Enterobacteriaceae) is a striking feature observed in 
Crohn's disease. No single factor has been definitely identified as driving this dysbiosis; 
instead, a host of  environmental factors—such as the diet, antibiotic exposures and possible 
early life  infections—in the presence of underlying genetic susceptibilities may contribute to 
the overall pathogenesis of Crohn's disease [17].
In CF patients, composition of the microbiome of pulmonary and gastrointestinal tracts changes 
over time, presumably as a consequence of inflammation [19]. Most research studies have dem-
onstrated the influence of inflammation in negatively selecting against potential pathogens. 
Moreover, some bacterial species may also have the ability to exploit  inflammatory byproducts 
for their benefit, which may promote their natural selection in inflamed habitats [20]. Reactive 
nitrogen species produced during inflammatory responses can be exploited by pathogens for 
their growth. Moreover, inflammatory mediators can provide an  environment for some bac-
teria to grow and use these inflammatory mediators for their survival [21]. Examples of such 
bacteria include Escherichia coli and P. aeruginosa in the gastrointestinal and respiratory tracts 
of CF patients, respectively. P. aeruginosa uses nitric oxide produced in the process of inflam-
mation for its anaerobic respiration and promotes its growth in  inflammatory environments. 
Likewise, E. coli uses increased nitrate in the environment for its anaerobic  respiration and 
enhances its growth in the inflamed gut of CF patients [19].
3. Heterogeneity of the CF airway microbiome
Due to defects in innate immunity, CF patients are prone to polymicrobial infections and their 
airway microbiome changes continuously and evolves over time. The primary cause of death 
in CF patients is respiratory failure due to persistent and recurrent pulmonary infections 
with different pathogenic organisms [22]. Over the past decade, the median survival for such 
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patients stands at 37 years despite increases in life expectancy [23]. MSSA and H. influenzae 
are one of the most common pathogens cultured from sputum samples of affected children. 
P. aeruginosa has been associated with increased morbidity as most strains of this organism 
are multidrug resistant. Infections with bacteria of the Bukholderia cepacia complex (BCC) are 
associated with a worse prognosis [24]. Likewise, other multidrug resistant organisms, such 
as Achromobacter xylosoxidans and Stenotrophomonas maltophilia, can also be isolated from CF 
patients with end‐stage pulmonary disease [25]. Nontuberculous mycobacterium (NTM) has 
also been identified as emerging causes of infections in patients with CF and their incidence 
may have been underestimated in the past [26]. More recently, research studies have shown 
that when sputum samples obtained from adults with CF are cultured, a significantly high 
density of anaerobic bacteria can be isolated—the most common of which are Streptococcus 
milleri, Prevotella spp., Actinomyces, and Veillonella [27].
Microbes of the lower airways in all humans exist in a dynamic state. Literature published 
on microbiome of CF patients has shown a complex and dynamic interaction between 
 different organisms in the airways of such patients [28]. Organisms within a single patient 
are  genetically and phenotypically diverse and heterogeneity is detectable even in different 
parts of the same lung. Over a period of time, community diversity of bacteria declines in CF 
patients as pulmonary function declines and lung disease progressively worsens. Studies have 
shown that diversity of microbial communities correlates positively with pulmonary function 
and outcome [29]. Such diversity was previously unrecognized as most studies relied solely 
on culture‐based methods of culturing bacteria. However, novel state‐of‐the‐art molecular 
techniques (such as Sanger sequencing of clone libraries, terminal restriction fragment length 
polymorphism [RFLP] analysis and microarray hybridization) have enabled the detection of 
subtle molecular diversity among seemingly similar bacterial species [30]. This diversity may 
be influenced by a number of factors including the patient's age, sex, type of CFTR mutation, 
antibiotic exposures, environmental factors, and extent and severity of lung disease. In a study 
by Zhao et al., sputum samples were collected from six CF patients over a period of 10 years. 
Of a total of 126 sputum samples, 662 operational taxonomic units (OTU) were identified and 
each patient had 5–114 different OTUs [29]. Similarly, in another  observational study, sputum 
samples of patients with acute infective exacerbation of non‐CF related bronchiectasis were 
collected. Sputum cultures from each patient contained large quantities of multiple bacterial 
species with a single predominant pathogenic species [31]. In one study, polymerase chain 
reaction (PCR)‐temporal temperature gel electrophoresis (PCR‐TTGE) was used to evaluate 
intraspecific and intragenomic 16S rDNA variability among commonly isolated respiratory 
pathogens from CF patients [32]. Significant discordance in intraspecific and intragenomic 
variability was noted among different bacterial species with H. influenzae displaying the high-
est level of intraspecific variability.
4. Composition of the CF microbiome and its determinants
The composition of the airway microbiome in CF patients is dependent on a number of 
 factors including geographic variation (more common in white population), type of genetic 
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 mutation (e.g., ΔF508), antibiotic exposures, and chronic infection with certain pathogenic 
bacteria (e.g., P. aeruginosa) [8]. Fetal lungs are sterile, just like fetal gastrointestinal tract, but 
they soon become colonized after birth. Fetal skin becomes colonized with microbes  present 
in maternal reproductive and gastrointestinal tracts and lungs become colonized from 
gut flora of the child [33]. The common phyla found in healthy lungs include Bacteroides, 
Firmicutes, and Proteobacterium. Other genera include Prevotella, Veillonella, Streptococcus 
and Pseudomonas [34]. Many techniques have been used for the detection of microbes in 
CF patients. Some of these techniques include terminal RFLP profiling, microarray analysis, 
clone library sequencing, and pyrosequencing. The most frequently used samples from CF 
patients for analysis are expectorated sputum, tracheal aspirates, bronchial washings, and 
bronchoalveolar lavage (BAL).
The microbiome in patients with CF evolves as patients grow older, and this is a  consequence 
of the wide adaptability of pathogenic bacteria. Clustering of phylogenetically similar 
 bacterial communities and loss of the architectural diversity of the airway microbiome is a key 
feature of late‐stage CF airway disease. Moreover, the type of bacterial species  predominating 
at a particular age group is also of immense importance. In one study, phylogenetic  diversity 
of CF airway microbiota in patients of different age groups was studied using microarray 
 analysis [35]. S. aureus was detected in 65% of sputum samples and was more common in 
the pediatric population (72% of the pediatric sample). Pseudomonas spp. was found in 73% 
of samples and were most common in adults (91% of the adult sample). In the same study, 
older CF patients had reduced airway bacterial diversity and aggregation of relatively  similar 
 organisms; this process occurred in conjunction with a progressive decline in pulmonary 
 function. H. influenzae was most prevalent in the pediatric population when the bacterial 
diversity was highest. Conversely, P. aeruginosa was most common in older individuals with 
a lower level of bacterial diversity. Likewise, members of the Mycobacteriaceae family and 
obligate intracellular pathogens (such as Chlamydia and Mycoplama spp.) were more preva-
lent in younger CF patients. Certain known or potential pathogens of CF patients, such as 
members of the Burkholderiaceae and Thermoactinomycetaceae families, were almost exclu-
sively observed among adult patients.
In another study [29], CF patients with progressive lung disease were noted to have a 
decrease in bacterial diversity with increasing age, but the total bacterial density remained 
stable over time. Antibiotic exposures in conjunction with recurrent pulmonary  exacerbations 
were  proposed as a possible contributing factor toward this observation. In a study by 
Tunney et al., several anaerobic species (including a number of Veillonella and Prevotella 
species) constituted a significant portion of the CF airway microbiota [36]. In a unique study, 
next generation sequencing was used to study the microorganisms of gastric juice among 
patients with CF and non‐CF controls [37]. CF gastric juice was noted to have an abundance 
of Pseudomonas spp. and a relative paucity of normal gut bacteria (such as Bacteroides and 
Faecalibacterium), which was in contrast with normal gastric juice samples. These results 
suggest that CF patients possess a unique aerodigestive microbiome that is inter‐related. This 
explanation seems plausible as the factors that influence the airway microbiome (for instance, 
antibiotic exposures) are also likely to influence the microbiota of gut and other organ‐systems 
of the body [38].
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In patients with CF, different bacterial colony morphotypes can be isolated from a single 
 sputum sample. There is some evidence to suggest that these different morphotypes arise 
from a single bacterial strain [39]. Microbes in the lungs of CF patients are capable of 
 constantly adapting to selection pressures. Some of the mechanisms that enable the  evolution 
of microbes include motility, type III secretion systems, lipopolysaccharide, plasmids 
( encoding for  antibiotic resistance), biofilm formation, small colony variants, quorum  sensing, 
and  hypermutability. As a consequence of these mechanisms, different phenotypes arise from 
a single bacterial species and, over time, a single bacterial strain with dominating features 
may evolve [40]. Given that different bacterial strains have differing capacities to evolve, 
 multiple lineages of bacterial colonies evolve and coexist [41]. Some studies have shown that 
 complexity of bacterial communities inversely correlates with patient age, antibiotic expo-
sures, and  presence of P. aeruginosa [42]. In one study, heterozygosity for the ΔF508 mutation 
and presence of mutations other than the ΔF508 was associated with relative preservation of 
airway bacterial diversity over time [35]. This shows that apart from environmental exposures 
(such as antibiotic pressures), patients’ genotype (type of mutation) also plays an important 
role in determining the composition of the CF airway microbiome. In terms of  environmental 
exposures, antibiotic use has been shown to be the prime factor that adversely affects  microbial 
diversity among CF patients [29]. Loss of bacterial diversity (under the selection pressure of 
antibiotics) has been associated with an increased risk of pneumonia in mechanically venti-
lated patients colonized with P. aeruginosa [43]. Smith et al. studied this further by performing 
whole genomic analysis of a single species of P. aeruginosa isolated from a patient with CF. 
Whole genomic sequencing was repeated multiple times during the course of the patient's 
 illness, which enabled the detection of an overwhelming number of mutations. Based on these 
analyses, it was found that the strain of P. aeruginosa that inhabits patients with advanced CF 
differs significantly from wild‐type P. aeruginosa [40].
The interaction among different bacterial colonies has also become a subject of intense research 
and genomic and proteomic approaches are currently being used to understand their inter-
relationships. In an experimental study, production of 4‐hydroxy‐2‐heptylquinoline‐N‐oxide 
(HQNO) by a strain of P. aeruginosa enhanced the aminoglycoside resistance of S. aureus [44]. 
This study provided some evidence of how bacterial interspecies interaction can alter the 
airway microbiome by selecting for resistant strains of a bacterial species. Previous studies 
have shown that HQNO is detectable in the sputum of infected CF patients. Therefore, an 
interaction between P. aeruginosa and S. aureus may account for the increased incidence of 
small colony variant (SCV) of S. aureus species in CF patients with advanced lung disease.
In the recent literature, an increasing number of unusual microbes have been reported as the 
cause of infective exacerbations of CF. Such bacteria include multidrug resistant pathogens 
like S. maltophilia, multidrug resistant P. aeruginosa, MRSA, Burkholderia cenocepacia and even 
NTM [45]. The emergence of such bacteria as members of the CF airway microbiome can have 
important implications for management and prognosis for patients. For instance, studies have 
shown that in CF patients with an acute exacerbation, there is discordance between the results 
of microbial sensitivity testing and response to antibacterial therapy [46]. Polymicrobial 
 infections and presence of fastidious organisms may account for this  observation. Moreover, 
such pathogenic bacteria can interact with other less virulent bacterial species and lead to 
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architectural distortion of the entire CF microbiome. In the following lines, we discuss 
 common members of the CF airway microbiome, some of which are commonly implicated in 
infective exacerbations.
4.1. Methicillin‐sensitive Staphylococcus aureus
S. aureus is a common colonizer of the anterior nares of adolescent and adult patients [47]. 
Among patients with CF, MSSA is one of the most common pathogens isolated from  sputum 
samples obtained for culture and sensitivity testing. In the CF Foundation (CFF) patient 
 registry (Bethesda, Maryland, USA), S. aureus was most commonly isolated from children and 
adolescents accounting for approximately 51% of the total samples. Moreover, the overall 
prevalence of S. aureus has been increasing over the past few decades. Infection with S. aureus 
has been associated with increased bronchial inflammation and decreasing pulmonary 
 function [48]. Moreover, when coinfection with P. aeruginosa and MSSA occurs, mortality is 
increased manifold. Interestingly, studies have shown that MSSA is associated with more 
severe disease in children as compared to adults.
With the widespread use of antistaphylococcal antibiotics, incidence of Gram‐negative 
 infections among CF patients has increased and MSSA has become less common among 
adult patients. Overall, the most common cause of chronic lung infections in CF patients is 
P.  aeruginosa, an oxidase‐positive Gram‐negative bacillus. Moreover, as CF patients grow 
older, MRSA becomes a more frequent cause of infective exacerbation than MSSA. Over 
the past few years, the incidence of MRSA infections has been steadily increasing, owing to 
increasing use of antistaphylococcal penicillins (such as oxacillin and nafcillin) [49]. More 
recently, a subtype of S. aureus species (viz. small colony variant) has been isolated more 
frequently from CF patients. The small colony variant of S. aureus species is fastidious and 
slow‐growing, and it has also been associated with rapid decline in pulmonary function. As 
mentioned previously, selection of small colony variant species is promoted by HQNO—a 
product synthesized and secreted by P. aeruginosa species [44]. Increasing use of broad‐spec-
trum antibiotics that select for multidrug resistant pathogens can explain this distortion in the 
composition of the airway microbiome in patients with CF.
4.2. Methicillin‐resistant Staphylococcus aureus
S. aureus is typically the first bacterial pathogen to invade the pulmonary parenchyma in 
patients with CF. Chronic infection with this organism can persist in the airways of CF patients 
for several years. Acquisition of mecA gene mediates methicillin resistance in  community‐
acquired MRSA by encoding for a mutated penicillin binding protein‐2A (PBP‐2A) [50]. The 
prevalence of MRSA has increased substantially over the past several years from an esti-
mated 7.3% in 2001 to 22.6% in the year 2008 and 25.7% in 2012 [10]. This increase in preva-
lence of MRSA was noticed across CF patients of all age groups with the highest increase 
being in the adolescent age bracket. This increase in the prevalence of MRSA in CF patients 
has been directly linked to the increase in overall incidence of community‐acquired MRSA in 
the  general population [51]. In a study by Glikman et al., 22 of 34 (64.7%) MRSA isolates from 
patients with CF contained the gene SCCmec II—a typical feature of health‐care associated 
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MRSA strains. On the other hand, 9 of 34 (26.5%) MRSA strains harbored the SCCmec IV 
gene, which characterizes them as community‐acquired MRSA strains. Most patients with 
 community‐acquired MRSA were newly colonized with the strain. Additionally, children 
with CF were more likely to harbor MRSA isolates that were resistant to clindamycin and 
ciprofloxacin compared with strains from non‐CF patients [52]. Other studies have reported 
persistent infections in CF patients with both hospital‐acquired and community‐acquired 
MRSA strains (including Panton‐Valentine leukocidin‐positive strains) with an overall prev-
alence of 7.8% [53]. In these studies, persistence was due to presence of different clones 
over time or identical clones that underwent minor modifications in their toxin content. 
Moreover, isolation of MRSA from CF patients aged 7–24 years has been associated with 
an increased severity of the disease. Alarmingly, some of these strains may be vancomy-
cin‐intermediate S. aureus (VISA), which implies that treatment with glycopeptides (such as 
vancomycin) may also be ineffective. Highly virulent strains, such as vancomycin‐resistant 
S. aureus (VRSA), have also been reported to cause necrotizing pneumonia in a small number 
of CF patients [54]. Persistent infection with virulent strains of S. aureus has been associated 
with a rapid decline in pulmonary function [55]. In a case‐control study, CF patients who 
were colonized with MRSA had a significantly higher rate of decline in FEV
1
 (forced expira-
tory volume in first second) as compared to those who were not colonized with MRSA [56]. 
Moreover, MRSA‐infected CF patients have been shown to have longer hospital stays than 
age‐ and sex‐matched controls [57]. Serious manifestations of MRSA infections have also 
been described in various reports. Cavitary lesions have been described in two CF patients 
infected with Panton‐Valentine  leukocidin‐positive MRSA strains [54]. This observation was 
consistent with other reports of serious pulmonary manifestations of community acquired 
MRSA  infection [54, 58]. In a cohort study of longitudinal data, risk of death among CF 
patients who had at least one culture positive for MRSA was 1.27 times greater than for CF 
patients in whom MRSA was never detected [55]. In a meta‐analysis of 76 studies, a clear and 
strong association was noted between exposure to antibiotics and isolation of MRSA [59]. 
The risk of acquiring MRSA was increased by 1.8‐fold in patients who had taken antibiotics 
as compared to others. The risk ratios for quinolones, glycopeptides, cephalosporins, and 
other beta‐lactam antibiotics were 3, 2.9, 2.2, and 1.9, respectively.
4.3. Hemophilus influenzae
H. influenzae is a facultative, anaerobic, Gram‐negative bacillus. In many patients, this  organism 
begins to colonize the upper respiratory tract since infancy. Approximately 20% of infants 
with CF are colonized by the end of first year of life and the rate is even higher for patients 
of older ages [60]. By the age of 5–6 years, more than 50% of children are colonized with this 
bacterium [61]. H. influenzae is a common pathogen of chronic lung infections and is frequently 
implicated in infective exacerbations of CF [62]. In children with CF, about 32% are colonized 
with this microorganism. However, as these patients grow older and are exposed to a wide 
range of broad‐spectrum antibiotics, more virulent bacteria inhabit their respiratory tracts. 
Consequently, in adults with CF, the rate of colonization with H. influenzae is reported to be 
only 10–15%. Having said this, the prevalence of H. influenzae has increased from 10.3% in the 
year 1995 to 16.3% in the year 2008.
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Similar to the general population, colonization of the upper respiratory tract of CF patients 
with H. influenzae is quite a dynamic process. Children will typically carry multiple strains of 
this bacterium simultaneously, whilst adults will be colonized with only one strain [63]; again, 
this is a natural consequence of the loss of microbial diversity induced by antibiotic  selection 
pressures. Even in most healthy adults, the upper airway is colonized with H. influenzae; 
most strains in such healthy subjects are nontypeable. In particular, the nasopharynx is an 
area of the respiratory tract that serves as a potential reservoir of this bacterium. Eventually, 
the organism may spread from the nasopharynx to the lower respiratory tract and cause an 
 infection of the pulmonary parenchyma [64]. Studies have shown that most CF patients are 
cocolonized with two or more distinct strains of H. influenzae [65].
H. influenzae is not considered a virulent pathogen in patients with CF. Interestingly, some 
studies have shown that colonization with H. influenzae is associated with a relatively pre-
served lung function. This is in sharp contrast to other microorganisms like P. aeruginosa and 
MRSA, whose colonization of the pulmonary parenchyma is strongly associated with a rapid 
decline in lung function [66]. In a prospective study, 27 patients with CF (under the age of 
12 years) and 27 matched patients with asthma were followed up for 1 year [67]. The isolation 
rate of noncapsulated (nontypeable) strains of H. influenzae was significantly higher in the 
CF group as compared to that of the asthma group. During exacerbations, the isolation rate 
of H. influenzae in the CF group was significantly greater than at other times, whereas there 
was no significant difference in the control group. The distribution of biotypes of H.  influenzae 
and Hemophilus parainfluenzae was similar in the two groups. In the CF group,  biotype I was 
 commonly detected and was associated with infective exacerbations of CF. In contrast, 
 biotype V was more common in the asthma group, although it had no association with the 
 development of infective exacerbations [67].
4.4. Pseudomonas aeruginosa
P. aeruginosa is an obligate aerobic, oxidase‐positive, nonlactose fermenting  Gram‐nega-
tive rod. P. aeruginosa is the most common organism implicated in infective exacerbations 
in patients with CF. In the CFF patient registry (Bethesda, Maryland, USA), more than half 
of the patients (52.5%) were reported to be infected with P. aeruginosa in 1995. The risk of 
chronic infection with P. aeruginosa increased proportionately with increasing age. Moreover, 
the  incidence of P. aeruginosa has been reported to be increasing in infants. Despite changes in 
the management of patients with CF, the frequency of persistent infection with P.  aeruginosa 
has remained relatively stable over time [68]. In a study based on the CFF patient  registry, 
 prevalence of colonization with P. aeruginosa was 60% in 1995 and 56.1% in 2005 [69]. However, 
recent data suggest that the prevalence of P. aeruginosa is slowly decreasing over time and 
has been estimated to be 30.4% in the year 2015 [70].
The main reservoir of P. aeruginosa is the environment surrounding CF patients. It has been 
thought that among siblings with CF, prolonged exposure of young children to their older 
siblings with CF is a potential risk factor for acquisition of P. aeruginosa. A study published in 
1991 reported that P. aeruginosa may be acquired by patients at CF recreation camps,  clinics, 
and/or rehabilitation centers [71]. Studies on genotypes of P. aeruginosa performed using 
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conventional pyocin typing and DNA probe analysis reported that most CF patients har-
bored a persistent strain of P. aeruginosa in their lungs [72]. These studies suggested that 
cross‐colonization possibly could occur among patients. Another study showed that 59% of 
CF patients harbored a clonal strain of P. aeruginosa and the dominant pulsotype was indis-
tinguishable from nonclonal strains with respect to both colony morphology and resistance 
patterns [73]. Wolz et al. used DNA probe amplification assays and demonstrated that 46% 
of CF patients (who were initially uninfected) acquired P. aeruginosa infection at the end of 
a CF  recreation camp [74]. Clear evidence of a cross‐infection among patients attending a 
CF clinic was  published in 2001 [75]. In this study, 22 of 154 patients attending an adult CF 
clinic were chronically infected with similar isolates (based on pyocin typing and pulsed‐
field gel electrophoresis [PFGE] analysis) of P. aeruginosa that shared unusual phenotypic 
features: lack of motility and pigmentation along with a remarkable resistance to many anti-
biotics. In another study from a large pediatric CF clinic from Australia, 65 patients (55%) 
were found to be infected with a similar strain of P. aeruginosa. These patients were more 
likely to have been hospitalized in the preceding 1 year for respiratory exacerbations [76]. 
On the other hand, a study conducted by Speert et al. in Vancouver (Canada) reported a low 
rate of transmission of P. aeruginosa from one CF patient to the other [77]. In this study, a 
total of 157 genetic types of P. aeruginosa were identified, of which 123 were unique to indi-
vidual patients. These apparently  conflicting findings may be accounted for by the highly 
adaptable nature of P. aeruginosa and its ability to evolve. In a study by Mahenthiralingam et 
al., different strains of P. aeruginosa were studied using genomic fingerprinting and random 
DNA amplification assays [78]. A total of 385 isolates from 20 patients were grouped into 35 
random amplified polymorphic DNA (RAPD) strain types. Secretion of mucoid exopolysac-
charide, loss of expression of  RpoN‐dependent surface factors and acquisition of serum‐sus-
ceptible phenotypes in Pseudomonas were shown to be a specific adaptation to infection, 
rather than being acquired from a new bacterial strain. This explanation is also in congruence 
with observations from other studies that found  different strains of P. aeruginosa in unrelated 
CF patients and identical or closely related strains among siblings [79]. The presence of dis-
tinct strains of P.  aeruginosa in these studies reflects an absence of nosocomial transmission 
of organisms at respective CF centers [80]. This may be a consequence of strict hygiene mea-
sures and microbiologic surveillance instituted at most CF centers across the world following 
reports of nosocomial spread [75, 76].
The effects of P. aeruginosa infection on the CF lung are deleterious. In one observational 
study, outcomes of CF children colonized with P. aeruginosa were compared with those 
of noncolonized patients. Children colonized with P. aeruginosa had a worse outcome and 
 experienced rapid decline in pulmonary function as measured by FEV
1
 and FEF25 (forced expiratory flow at 25% of vital capacity) [81]. In another longitudinal observational study, the 
temporal relationship between P. aeruginosa infection and pulmonary damage (as  measured 
by FEV
1
 and Wisconsin additive chest radiograph score) was explored. Acquisition of 
P.  aeruginosa was independently associated with a worsening pulmonary status in children 
with CF [82]. Moreover, in these studies, decline in pulmonary function after colonization with 
P.  aeruginosa was observed to be gradual. This decline in pulmonary function associated with 
P. aeruginosa infection is noted across all age groups. In another study, acquisition of mucoid 
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strains of P. aeruginosa was associated with an unfavorable prognosis [83]. From a patho-
logic perspective, P. aeruginosa causes repeated airway infections with  eventual  progression 
to chronic airway infection. This organism can also lead to necrotizing  pneumonia, chronic 
 bronchopneumonia, and chronic parenchymal lung disease. While the aggressive use of 
antipseudomonal  antibiotics has been shown to delay the onset of chronic infection, preva-
lence rates of P. aeruginosa colonization have remained relatively stable over the past two 
decades [84, 85].
The CF airway provides a pathological milieu and a scaffold for chronic infection with 
resistant organisms, the most notable of them being P. aeruginosa. A number of virulent 
factors enable this resilient organism to establish it within the CF airways. One such viru-
lence factor—overproduction of alginate slime capsule—characterizes the mucoid type of 
P. aeruginosa, which allows it to adhere firmly to the airway epithelium. Being encoded 
by the AlgT gene, alginate negatively regulates flagella, fimbriae, and quorum sensing. 
TTSS (injectosome) positively regulates alginate production indirectly through heat shock, 
osmotic, and oxidative stress responses [86]. In the inflamed CF airway,  polymorphonuclear 
leukocytes (PMN) lead to the production of reactive oxygen species (ROS) and reactive 
 nitrogen  intermediates (RNI) [87]. Moreover, mutated CF epithelial cells are unable to 
efflux glutathione (a potent free radical scavenger) and unable to absorb other dietary 
 antioxidants. Production of ROS and RNI by PMN leads to DNA damage, lipid peroxida-
tion and  denaturation of proteins. At the same time, RNI and ROS lead to upregulation 
of alginate production by P. aeruginosa. The alginate slime capsule enables the bacterium 
to adhere firmly to the airway epithelial cells and results in persistence of this organism 
within the airways. At the same time, other virulence factors produced by P. aeruginosa 
(such as exotoxins) incur progressive pulmonary damage and help it to evade the (already 
impaired) host immune response. Over time, ROI and RNI lead to loss of microbial diver-
sity and disruption of the airway microbiota. Simultaneously, such an environment favors 
the survival and selection of P. aeruginosa within the CF airway and leads to persistent 
infection with this organism [88, 89]. Moreover, antibiotic exposures select for multidrug 
resistant variants of the organism and allow them to predominate and colonize the airways 
[24, 90]. Alarmingly, recent reports from CF centers across the world have described certain 
strains of P.  aeruginosa that exhibit resistance to all clinically relevant classes of antimicrobi-
als (“pan‐resistant” P. aeruginosa) [91]. This can explain the worse prognosis associated with 
this organism in most studies of CF patients.
4.5. Burkholderia cepacia complex
More than 60 species belonging to the genus Burkholderia are not pathogenic to humans, but 
some of the remaining species are implicated in serious infections in CF patients. Using 16S rDNA 
and recA gene analysis, 17 species of this genus have been grouped together as the Burkholderia 
cepacia complex (BCC). BCC is a group of virulent pathogens that are frequently implicated 
in infective exacerbations in CF patients with end‐stage lung disease. Colonization with BCC 
in CF patients indicates a poor prognosis and has been shown to be associated with a require-
ment for lung transplantation. This worse prognosis is due to the inherent antibiotic resistance 
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 possessed by these organisms and their ability to rapidly spread from patient to patient. In some 
cases, infection with BCC can lead to the development of cepacia syndrome—a rapid fulminat-
ing pneumonia that often leads to bacteremia and sepsis. Given their virulent nature, strict infec-
tion control measures are essential to prevent outbreaks of BCC in CF clinics and centers [92]. 
A report of rapid spread and outbreak of BCC infection was reported in a CF center in Toronto 
[93]. This center reported the development of cepacia syndrome in many patients, being char-
acterized by rapidly deteriorating pulmonary function, fever, leukocytosis, elevated markers of 
inflammation, and BCC bacteremia. Furthermore, in another report, cepacia syndrome occurred 
in approximately 20% of infected patients and had a case fatality rate of 62% [93].
Outside of the BCC group, a few other species of the Burkholderia genus are also implicated 
in infective exacerbations. These species include Burkholderia gladioli, Burkholderia fungorum, 
Burkholderia multivorans and Burkholderia pseudomallei [94]. Of these, B. gladioli now accounts for a 
significant proportion of Burkholderia infections in CF patients [95]. In the United States, B. multi-
vorans and B. gladioli together account for more than 50% of Burkholderia infections in CF patients.
Most infected CF patients harbor genotypically distinct strains of the BCC. Strains of Burkholderia 
spp. that are shared by multiple CF patients are very uncommon. This  suggests that most 
Burkholderia infections in CF patients result from acquisition of strains from the natural envi-
ronment [92, 96]. In this regard, B. gladioli and B. cepacia have been described as recognized 
plant pathogens. In one study, multilocus sequence typing of Burkholderia spp. revealed that 
more than 20% of CF isolates were identical to strains recovered from the  environment [97].
In the CFF patient registry, prevalence of BCC was reported to have declined from 9% in 1985 
to 4% in 2005. Incidence of BCC was also found to be reduced from 1.3% in 1995 to 0.8% in 
2005 [69]. This has not changed significantly over the past decade as shown by data published 
in 2016 [70]. Ramette et al. analyzed 285 confirmed isolates of BCC using restriction analysis of 
recA and identified seven different BCC species in the environment [98]. Healthcare‐associated 
outbreaks of BCC infections as a consequence of contaminated medical devices and products 
(such as mouthwashes, ultrasound gels, skin antiseptics, and medications) have been reported 
previously. While most of these outbreaks have generally involved non‐CF patients, the poten-
tial for developing such outbreaks among CF patients remains a hazard [99]. Infection of the 
respiratory tract with BCC species in CF patients often results in a chronic persistent infection 
[100]. In most such cases, a single strain of Burkholderia spp. colonizes the respiratory tract.
Infection with BCC species has been associated with a worse prognosis. In one study, CF patients 
who were infected with Burkholderia dolosa had a rapid decline in FEV
1
 over time [101]. In another 
study, patients colonized with B. cenocepacia had a worse outcome in terms of body mass index 
(BMI) and FEV
1
 as compared to those colonized with P. aeruginosa or B. multivorans [102].
4.6. Anaerobic bacteria
Anaerobic bacteria have been described in the airways of people with healthy lungs and are 
generally not considered to be pathogenic. In patients with CF, anaerobic bacteria are per-
sistent members of the lower airway community as the anaerobic conditions (and steep oxy-
gen gradients) in the lower airways provide an ideal environment for their growth [88, 103]. 
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However, in the CF lung, anaerobic bacteria can produce virulence factors and  damage the 
lung parenchyma (perhaps as a consequence of impaired innate immunity), which may worsen 
pulmonary function and exacerbate the inflammatory response. Short‐chain fatty acids pro-
duced by anaerobic bacteria can increase production of interleukin‐8 (IL‐8) by upregulating 
expression of the short‐chain fatty acid receptor GPR41 [104]. Moreover, in the CF microbi-
ome, anaerobic bacteria can interact with other established pathogens and lead to progressive 
pulmonary damage [105]. Previously, anaerobic bacteria were thought to be an infrequent 
cause of CF exacerbation; however, with the advent of novel (culture‐independent) micro-
bial detection methods [106–109], anaerobes have been isolated from more frequently. In one 
study, 23.8% of sputum specimens from CF patients grew more than 105 colony  forming units 
(CFU) per milliliter of anaerobic bacteria [110]. In another study, 15 genera of obligate anaer-
obes were identified in 91% of CF patients with counts (CFU/ml) being comparable to that of 
P. aeruginosa and S. aureus [111]. The most common anaerobes were Staphylococcus saccharo-
lyticus and Peptostreptococcus prevotii. Some studies suggest that patients with lower aerobic 
and anaerobic bacterial load have worse pulmonary function and higher levels of inflam-
matory markers [112]. From a biological standpoint, lower quantity of aerobes and anaer-
obes may reflect disruption of the CF microbiota. Studies have shown that antibiotic therapy 
directed against P. aeruginosa during acute exacerbations does not affect anaerobes [111]. This 
observation could be explained by considering the resistance patterns of anaerobes. In 58% of 
patients, obligate anaerobes detected during acute infective exacerbations were resistant to 
antibiotics used for treatment. The chief obligate anaerobes in such cases were Bacteroides spp., 
Porphyromonas spp., Prevotella sp., Veillonella, anaerobic Streptococcus spp., Proprionibacterium, 
Actinomyces, S. saccharolyticus and P. prevotii [36, 111, 113]. Interestingly, infection with P. aeru-
ginosa significantly increases the likelihood of isolating anaerobic bacteria from CF patients 
[36]. Some of these anaerobic bacteria (such as S. milleri) are now known to be associated 
with worse clinical outcomes. Furthermore, new anaerobic organisms have been detected for 
the first time from samples of CF patients. Such bacteria, for instance Gemella and Rothia 
mucilaginosa, have been found to be associated with dismal pulmonary outcomes. Most such 
patients are often coinfected with P. aeruginosa as well [114, 115].
4.7. Nontuberculous mycobacteria
Traditionally, the frequency of CF patients infected with NTM has been reportedly low. In the 
CFF patient registry, the prevalence of NTM infections among CF patients has been  estimated 
to be 2.2%. Nevertheless, the prevalence of NTM has been increasing slowly over the past 
few decades. The prevalence of NTM infection in 1999 among CF patients was 0.85%, which 
increased to 2.18% in 2008 [116]. More recent data published in 2016 shows that the prevalence 
of NTM may be as high as 11.9% [70]. The most common NTM species have been reported to 
be Mycobacterium avium‐intracellulare (MAI) complex and Mycobacterium  abscessus. Factors 
associated with a culture positive for NTM are older age, greater FEV
1
, higher frequency of 
MSSA colonization and lower frequency of P. aeruginosa infection [117]. In most patients, 
unique strains of NTM are detected by molecular typing, which suggests that neither per-
son‐to‐ person transmission nor nosocomial acquisition is implicated. In one study, the preva-
lence of NTM infection among 385 patients in three Parisian centers was 8.1%. M. abscessus 
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was  isolated in all age groups. About 4.1% (16/385) of the study cohort met the American 
Thoracic Society (ATS) criteria for NTM‐related lung disease [118]. In another  multicenter 
study done in Israel [119], prevalence of NTM‐related lung disease (as defined by the 2007 
ATS criteria) was 10.8%. This study further suggested that the incidence of NTM infections 
is increasing over time. Other studies have demonstrated that the incidence of MAI com-
plex infections in CF patients is decreasing with time, while that of M. abscessus complex is 
increasing [120]. Alarmingly, infection with M. abscessus complex has been associated with a 
worse impact on pulmonary function. Some researchers have proposed that eradication of M. 
abscessus  complex may  provide a significant improvement in terms of pulmonary outcome 
[121]. However, M. abscessus is difficult to manage, commonly affects younger children, and 
requires prolonged courses of intravenous antibiotics [122].
4.8. Stenotrophomonas maltophilia
S. maltophilia is a Gram‐negative bacillus that is commonly implicated in nosocomial  infections 
in non‐CF patients. However, in patients with CF, S. maltophilia has been  recognized as a cause 
of acute infective exacerbation. The medical importance of this pathogen is that it is inher-
ently resistant to a wide range of broad‐spectrum antibiotics (most notably carbapenems). 
The prevalence of infection with this organism has increased from 1 to 4% over a period of 
20 years (1985–2005) [68]. In the CFF patient registry, the prevalence of S.  maltophilia increased 
from 4.0% in 1996 to 12.4% in 2005 [69]. From 2005 till 2015, the prevalence of S. maltophilia 
seems to have plateaued [70]. S. maltophilia infections of the respiratory tract in CF patients 
tend to be acute and, in most cases, the organism does not persist in the lower airways 
(although recurrent infections can occur). Most isolates of this organism have been shown to 
be transmitted from patient‐to‐patient, especially among siblings, or those who are otherwise 
epidemiologically linked [123]. One‐third of CF patients who experience recurrent infections 
with S.  maltophilia harbor more than one strain of the organism [124]. The most important 
risk factors for acquiring S. maltophilia infections are therapy with carbapenems and cen-
tral venous catheterization [125]. In one study, history of treatment with imipenem was 10 
times more frequent among cases (who contracted S. maltophilia) than among controls [125]. 
Furthermore, all fatal infections with S. maltophilia occurred in patients who had received imi-
penem. Based on these results, it is advisable to cover S. maltophilia empirically in CF patients 
who develop super‐infection while receiving imipenem therapy. In a report by Sanyal and 
Mokaddas [126], most strains of S. maltophilia were susceptible to ciprofloxacin and trime-
thoprim‐sulfamethoxazole. Moreover, some evidence shows that CF patients infected with 
S. maltophilia were more likely to have been hospitalized for many days in the past one year 
[127]. Other factors associated with S. maltophilia acquisition were more than two courses of 
intravenous antibiotics, isolation of Aspergillus fumigatus or P. aeruginosa in sputum and oral 
steroid use [128]. S. maltophilia is also more common among CF patients who develop allergic 
bronchopulmonary aspergillosis (ABPA) [129]. While chronic infection with S. maltophilia is 
infrequent, it can occur in certain patients and requires repeated courses of antibiotics [130]. 
Chronic infection with S.  maltophilia confers a threefold higher risk of mortality or the need 
for lung transplantation [131].
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4.9. Achromobacter xylosoxidans
A. xylosoxidans has been recognized as a pathogen and cause of infective exacerbation in 
patients with CF [132]. In the CFF patient registry, the prevalence of A. xylosoxidans infec-
tion was 1.9% in 1995 [69]. In 2015, the prevalence had increased almost three‐folds to 6.1% 
[70]. A. xylosoxidans is a ubiquitous organism that occurs widely in natural habitats. This 
organism is an opportunistic pathogen that affects only immunocompromised patients and 
those with CF. A. xylosoxidans is mostly implicated in nosocomial infections, such as hospital 
acquired pneumonia, catheter‐associated urinary tract infection, and wound infections. Lung 
infections with this fastidious organism are difficult to eradicate. Most patients respond to 
antipseudomonal penicillins (such as piperacillin–tazobactam) and third‐ or fourth‐genera-
tion cephalosporins [133]. In one report, two cases of Achromobacter ruhlandii developed after 
indirect contact between CF patients [134]. Another study from a French CF center reported 
that most isolates of Achromobacter spp. were resistant to fluoroquinolones and carbapenems 
[135]. In a retrospective study, CF patients who were chronically infected with A. xylosoxidans 
were more likely to have impaired pulmonary function. Additionally, the frequency of hospi-
talization was higher among such patients than others [136].
5. Implications for further research
Cystic fibrosis is a monogenetic multisystem disorder, but, pulmonary disease is the lead-
ing cause of morbidity and mortality. Recurrent pulmonary infections with pathogenic bac-
teria can lead to progressive pulmonary damage and eventually lead to death. Therefore, 
understanding the CF airway microbiome has immense importance for understanding the 
overall pathology of the disease. Disruption of the CF airway microbiome under the influ-
ence of environmental factors and antibiotic exposures is a crucial step in the development 
of end‐stage pulmonary disease in such patients [40]. Colonization of the lower airways with 
pathogenic bacteria, such as P. aeruginosa [82] and B. cenocepacia [101], has been associated 
with end‐stage pulmonary disease.
As the CF airway microbiome evolves under the influence of antibiotic exposures, microbes 
undergo a number of mutations and changes in their genome [137]. While these genetic 
mutations are an evolutionary mechanism for microorganisms (for instance, to acquire resis-
tance to antibiotics), they create potential vulnerabilities that may be exploited in unique 
therapeutic approaches. Traditionally, the approach to management of CF pulmonary exac-
erbations has been through employment of antibiotics. While antibiotics are useful in the 
short run, multidrug resistant microbes eventually evolve and become a challenge to tackle. 
In view of this, novel approaches to the management of CF pulmonary disease have been 
proposed, which involve manipulating patients’ microbial consortia [8]. From a theoretical 
perspective, such an approach aims to maintain the architecture of the CF airway microbiome 
and avoids the use of antimicrobials, thereby circumventing the problem of destroying the 
community structure of a patient's microbiome. Such a novel treatment approach is based on 
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the principles of personalized medicine and aims to tailor treatment according to each patient's 
individual microbiome [138]. By manipulating and restoring the structure of a patient's airway 
microbiome, the complex metabolomic profile of the patient's sputum (and other body fluids) 
can be altered, which may have long‐lasting and pleiotropic consequences [139].
Novel treatment approaches for the treatment of CF patients hold theoretical  promise, but 
their practical applicability and clinical efficacy remains to be established [140]. A recent 
pilot study compared the use of a probiotic (Lactobacillus spp.) versus placebo in  pediatric 
CF patients. Patients receiving the probiotic demonstrated a significant reduction in 
 hospitalization for pulmonary exacerbation and a beneficial effect on the gut in terms of 
reducing  gastrointestinal inflammation [141]. Another clinical trial examined the efficacy 
of enteric probiotics in reducing the frequency and severity of pulmonary exacerbations in 
CF patients. Both studies reported that the use of enteric probiotics provided a significant 
 reduction in the frequency of pulmonary exacerbations when compared to the placebo group 
[142]. Larger randomized controlled studies are needed to more fully evaluate the effect of 
probiotics on hard clinical endpoints [143]. Other treatment options based on these novel 
concepts need to be developed further, and they may help to improve the overall outcomes 
of patients with CF [144].
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